Processa Pharmaceuticals, Inc. Deferred Income Tax Expense (Benefit)
Processa Pharmaceuticals, Inc. (PCSA) reported Deferred Income Tax Expense (Benefit) of -$530.61 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2023-03-30
- Processa Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2021-12-31 was -$181.75K.
- Processa Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2021-09-30 was -$122.44K.
- Processa Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2021-06-30 was -$137.17K.
- Processa Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2021-03-31 was -$89.25K.
- Processa Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2021 was -$530.61K.
- Processa Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2020 was -$1.00M.
- Processa Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2019 was -$602.72K.
- Processa Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2018 was -$902.80K.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|
| 2021-12-31 | -$181.75K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$304.19K derived: sum of 2 quarters · filed 2023-03-30 | -$441.36K derived: sum of 3 quarters · filed 2023-03-30 | -$530.61K 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$122.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$259.61K derived: sum of 2 quarters · filed 2022-11-08 | -$348.86K 10-Q · filed 2022-11-08 | -$1.06M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | -$137.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$226.42K 10-Q · filed 2022-08-11 | -$941.01K derived: sum of 3 quarters · filed 2022-08-11 | -$1.01M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$89.25K 10-Q · filed 2022-05-12 | -$803.85K derived: sum of 2 quarters · filed 2022-05-12 | -$874.30K derived: sum of 3 quarters · filed 2022-05-12 | -$962.14K derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$714.60K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$785.05K derived: sum of 2 quarters · filed 2022-03-30 | -$872.89K derived: sum of 3 quarters · filed 2022-03-30 | -$1.00M 10-K · filed 2022-03-30 | |
| 2020-09-30 | -$70.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$158.29K derived: sum of 2 quarters · filed 2021-11-12 | -$286.42K 10-Q · filed 2021-11-12 | -$446.99K derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | -$87.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$215.96K 10-Q · filed 2021-08-12 | -$376.53K derived: sum of 3 quarters · filed 2021-08-12 | -$517.78K derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | -$128.13K 10-Q · filed 2021-05-13 | -$288.69K derived: sum of 2 quarters · filed 2021-05-13 | -$429.94K derived: sum of 3 quarters · filed 2021-05-13 | -$600.55K derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | -$160.56K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$301.81K derived: sum of 2 quarters · filed 2021-03-25 | -$472.42K derived: sum of 3 quarters · filed 2021-03-25 | -$602.72K 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$141.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$311.85K derived: sum of 2 quarters · filed 2020-11-12 | -$442.15K 10-Q · filed 2020-11-12 | -$573.62K derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | -$170.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$300.90K 10-Q · filed 2020-08-05 | -$432.37K derived: sum of 3 quarters · filed 2020-08-05 | -$644.38K derived: sum of 4 quarters · filed 2020-08-05 | |
| 2019-03-31 | -$130.30K 10-Q · filed 2020-05-15 | -$261.77K derived: sum of 2 quarters · filed 2020-05-15 | -$473.78K derived: sum of 3 quarters · filed 2020-05-15 | -$751.57K derived: sum of 4 quarters · filed 2020-05-15 | |
| 2018-12-31 | -$131.47K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | -$343.48K derived: sum of 2 quarters · filed 2020-03-06 | -$621.27K derived: sum of 3 quarters · filed 2020-03-06 | -$902.80K 10-K · filed 2020-03-06 | -$1.23M 10-K · filed 2019-03-28 |
| 2018-09-30 | -$212.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$489.80K derived: sum of 2 quarters · filed 2019-11-14 | -$771.33K 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | -$277.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$559.32K 10-Q · filed 2019-08-14 | |||
| 2018-03-31 | -$281.53K 10-Q · filed 2019-05-14 | ||||
| 2017-12-31 | -$166.79K 10-K/A · filed 2019-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |